Lexeo Therapeutics, Inc. (LXEO)
$2.74-9.87%Close
SELLCRISIS · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $215M
- Beta
- 1.64
- P/E (TTM)
- -2.38
- Short % float
- 40.59%
- Days to cover
- 9.0
- SI change
- -6.7%
- 1W
- -16.97%
- 1M
- -34.92%
- vs SPY 1W
- -16.83%
- vs SPY 1M
- -37.42%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 10
- GROWTH
- 47
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-25.1%
REV YoY-
ROE-41.9%
EPS YoY-
ROA-34.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-2.38
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.00
P/FCF-
EV/EBITDA-1.52
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.90
ALTMAN Z-
CURR RATIO13.89
ND/EBITDA-
BETA1.64
Company news
FAQ
- What is LOPJLB’s current signal on LXEO?
- LOPJLB’s latest quantitative signal on Lexeo Therapeutics, Inc. Common Stock (LXEO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LXEO in?
- Lexeo Therapeutics, Inc. Common Stock (LXEO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Lexeo Therapeutics, Inc. Common Stock (LXEO) do?
- Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting …